DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| 64.59 | |
| 64.59 | |
| - | |
| 64.59 | |
| 64.59 | |
| 56.8-131.88 | |
| 25 247 M | |
| 42.4934 | |
| 391 M | |
| 3 954 M | |
| 1.18 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
DexCom stock was falling Friday after the maker of glucose monitoring devices reported slowing revenue in the U.S. DexCom reported third-quarter adjusted earnings for the period ended Sept. 30, of 45 ...
Dexcom stock crashed late Thursday though the diabetes devices player beat third-quarter expectations and reiterated its guidance. Continue reading View comments
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
